Nerlynx Approved to Help Prevent Breast Cancer ' s Return

TUESDAY, July 18, 2017 -- Nerlynx (neratinib) has been approved by the U.S. Food and Drug Administration to help prevent HER2-positive breast cancer from returning.
It ' s the first drug designed to prevent return of HER2-positive breast cancer, a...

Source: Drugs.com - Daily MedNews - July 18, 2017 Category: General Medicine Source Type: news